tbuckley/cabot-search huggingface dataset:
LBA29 Aspirin after standard adjuvant therapy for colorectal cancers (ASCOLT): An international, phase III, randomised, placebo-controlled trial
Authors: J.W.K. Chia, E. Segelov, Y. Deng, W. Wang, G.F. Ho, A. Sharma, K. Ding, G. Chen, G.M. Jeffery, L.M. Nott, R. Zielinski, J.B. Ahn, T-Y. Chao, T. Yau, S. Nabilah, M. Gandhi, P. Rothwell, J. Simes, R. Ali, H.C. Toh
Journal: Annals of Oncology (2023)
LBA31 Neoadjuvant nivolumab plus relatlimab (anti-LAG3) in locally advanced MMR-deficient colon cancers: The NICHE-3 study
Authors: Y.L. Verschoor, J. van den Berg, S. Balduzzi, J.C. van Blijderveen, S. Oosterling, P. Burger, T. Aukema, T. Vogten, S. Dokter, R. Beets-Tan, A.V. Lent, G. Beets, M. van Leerdam, J.B.A.G. Haanen, M. Chalabi
Journal: Annals of Oncology (2023)
LBA32 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study
Authors: K-K. Shiu, T. André, T.W. Kim, B. Vittrup Jensen, L.H. Jensen, C.J.A. Punt, D. Smith, R. Garcia-Carbonero, J. Alcaide-Garcia, P. Gibbs, C. de la Fouchardiere, F. Rivera, M.E. Elez Fernandez, D.T. Le, T. Yoshino, Y. Zuo, D. Fogelman, D.E. Adelberg, L.A. Diaz
Journal: Annals of Oncology (2023)
LBA44 Camrelizumab plus famitinib versus camrelizumab alone and investigator’s choice of chemotherapy in women with recurrent or metastatic cervical cancer
Authors: X. Wu, L. Xia, K. Zhang, Y. Tang, G.N. Zhang, D. Wang, H. Lou, N. Liu, H. Zhang, H. Chen, K. Wang, S. Wei, L. Wang, K. Gao, G. Li, H. Zhang, Y. Hu, X. Zhou, Y. Wang, Q. Wang
Journal: Annals of Oncology (2023)
LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study
Authors: P. Schmid, J. Cortés, R.A. Dent, L. Pusztai, H.L. McArthur, S. Kummel, C. Denkert, Y.H. Park, R. Hui, N. Harbeck, M. Takahashi, T. Foukakis, M.A. Mouret Reynier, M.I.R. Ferreira, S-A. Im, F. Cardoso, Y. Ding, W. Pan, K.E. Tryfonidis, J. O'Shaughnessy
Journal: Annals of Oncology (2023)
LBA25 Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: A randomized phase III trial (UNION)
Authors: T. Zhang, K. Tao, Z. Lin, P. Zhang, Y. Yin, P. Chi, Y. Huang, Y. Xiao, Z. Sun, X. Xu, A. Zhang, X. Qiu, W. Junxin, Y. Yuan, Z. Wang, X.J. Qu, F. Zhao, C. Ma, F. Cheng, Z. Hou
Journal: Annals of Oncology (2023)
LBA19 Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study
Authors: L. Gianni, C. Huang, D. Egle, B. Bermejo, C. Zamagni, M. Thill, A. Anton Torres, G. Bianchini, E. Sevillano Fernandez, S. Russo, E.M. Ciruelos, R. Greil, V. Semiglazov, M.A. Colleoni, C.M. Kelly, G. Mariani, L. Del Mastro, R. Spezia, H. Ali, G. Viale
Journal: Annals of Oncology (2023)
LBA35 BNT211-01: Interim results from a repeat dose escalation study of CLDN6 CAR-T cells manufactured with an automated process ± a CLDN6-encoding CAR-T cell-amplifying RNA Vaccine (CARVac)
Authors: A. Mackensen, J.B.A.G. Haanen, W. Alsdorf, C. Koenecke, E. Wagner-Drouet, P. Borchmann, D. Heudobler, A. Busse, S. Klobuch, N. Kutsch, F. Müller, C. Bokemeyer, A. Desuki, F. Lueke, T. Ho, K. Vemuri, L. Preussner, B. Rengstl, Ö. Türeci, U. Sahin
Journal: Annals of Oncology (2023)
LBA37 Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) &gt;6 months: Primary analysis of the double-blind placebo (pbo)-controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial
Authors: A. Gonzalez Martin, M.J. Rubio Perez, F. Heitz, R.D. Christensen, N. Colombo, T. Van Gorp, A. Oaknin, A. Leary, L. Gaba Garcia, C. Lebreton, L.M. De Sande González, M. Romeo Marin, A. Redondo, M.P. Barretina Ginesta, J.A. Perez Fidalgo, A. Santaballa Bertran, M.J. Bermejo-Pérez, I. Bruchim, I.L. Ray-Coquard, F. Selle
Journal: Annals of Oncology (2023)
LBA43 Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial
Authors: R.N. Eskander, M. Sill, A. Miller, L. Beffa, R. Moore, J. Hope, F. Musa, R. Mannel, M.S. Shahin, G. Canturia, E. Girda, C. Mathews, J. Kavecansky, C.A. Leath, L. Gien, E. Hinchcliff, S. Lele, M.A. Powell, C. Aghajanian
Journal: Annals of Oncology (2023)
LBA45 Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa)
Authors: J.F. Liu, M. Brady, U.A. Matulonis, A. Miller, E.C. Kohn, E. Swisher, W. Tew, N. Cloven, C. Muller, D. Bender, R. Moore, D. Michelin, S. Waggoner, M. Geller, K. Fujiwara, S. D'Andre, M. Carney, A.A. Secord, J. Walker, M.A. Bookman
Journal: Annals of Oncology (2023)
LBA26 Neoadjuvant chemotherapy with CAPOX versus chemoradiation for locally advanced rectal cancer with uninvolved mesorectal fascia (CONVERT): Final results of a phase III trial
Authors: P-R. Ding, X-Z. Wang, Y-F. Li, Y-M. Sun, C-K. Yang, Z-G. Wu, R. Zhang, W. Wang, Y. Li, Y-Z. Zhuang, J. Lei, Y. Ren, X. Wan, Y. Cheng, W-L. Li, Z-Q. Wang, Z. Pan, Y.H. Gao, Z-F. Zeng, D-S. Wan
Journal: Annals of Oncology (2023)
LBA42 Olaparib vs placebo as maintenance therapy after platinum-based chemotherapy in advanced/metastatic endometrial cancer patients: The GINECO randomized phase IIb UTOLA trial
Authors: F. Joly Lobbedez, A. Leary, I.L. Ray-Coquard, B. Asselain, M.J. Rodrigues, L. Gladieff, F. Bazan, S. Abadie Lacourtoisie, C. Lebreton, L. Bengrine Lefevre, K. Leroy, R. Leman, P. Fournel, R. Largillier, F. Selle, J-S. Frenel, Y. Fernandez, C. Foa, B. You, J. Alexandre
Journal: Annals of Oncology (2023)
LBA47 A phase II study evaluating tipifarnib in mHRAS, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study)
Authors: A.L. Ho, D.R. Adkins, G.J. Hanna, J. Bruce, M-J. Ahn, L. Iglesias Docampo, H. Kang, D.J. Wong, A. Psyrri, M. Gillison, I. Braña, Y.C. Liu, C-Y. Hsieh, M.H. Hong, Z. Zhang, B. Balsara, A. Saunders, A. Gasco Hernandez, S. Dale, R. Haddad
Journal: Annals of Oncology (2023)
LBA38 Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
Authors: D. Lorusso, Y. Xiang, K. Hasegawa, G. Scambia, M.H. Leiva Galves, P. Ramos Elias, A. Acevedo, J. Vizkeleti, A.J.P.D.S. Gomes, F. Contreras Mejia, A. Reiss, A. Ayhan, J-Y. Lee, V. Saevets, F. Zagouri, K. Li, K. Ussui Yamada, S. Toker, S. Pignata, L.R. Duska
Journal: Annals of Oncology (2023)
LBA24 Multiparametric prognostic score in early HR+/HER2- breast cancer: Impact of recurrence score, clinical-pathological factors, gene mutations and histology
Authors: O. Gluz, M. Christgen, C. zu Eulenburg, U.A. Nitz, S. Kummel, M. Braun, B. Aktas, K. Luedtke-Heckenkamp, H. Forstbauer, E-M. Grischke, C. Schumacher, R.F.L. Baehner, R.E. Kates, M. Graeser, R. Würstlein, H. Kreipe, N. Harbeck
Journal: Annals of Oncology (2023)
LBA16 Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)
Authors: L. Mileshkin, T. Bochtler, C. Pauli, G. Durán-Pacheco, C. Arslan, F. Bigot, N. Chalabi, N. Cook, A. Italiano, F. Losa, J. Menezes, C. Michaud, M. Ozguroglu, R.A. Pazo Cid, J.S. Ross, K-K. Shiu, M. Stahl, M. Thomas, H. Moch, A. Krämer
Journal: Annals of Oncology (2023)
LBA34 Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study
Authors: F. Meric-Bernstam, V. Makker, A. Oaknin, D-Y. Oh, S. Banerjee, A. Gonzalez Martin, K.H. Jung, I. Lugowska, L.M. Manso, A. Manzano, B. Melichar, S. Siena, D. Stroyakovskiy, A. Fielding, Y. Ma, S.D. Puvvada, J-Y. Lee
Journal: Annals of Oncology (2023)
1759MO Clinical breast examination for early diagnosis of breast cancer: An Egyptian nationwide study
Authors: H.A. Azim, L. Kassem, K.S. Shohdy, Y. Safwat, E. Khallaf, S. Naguib, M. Hegazy, A. Selim, N. Hussein, A.H. Abdelaziz, H.A. El Ghazaly, M. Hassany, A. Abdelaziz, A.E.A. Kandil, B.A. El Sayed, T. Hashem, S.S.M. Eid, A. Morsy, K. Abdelghaffar, H. Zaid
Journal: Annals of Oncology (2023)
LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head &amp; neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy
Authors: N. Mach, E. Fernandez, R. Vernet, None O. Vonrohr, M. Urwyler, E. Charrier, M-C. Belkouch, V. Saingier, None F. Courtout, None C. de Vito, O. Rubin, V. Ancrenaz, J.N. Grogg, J. Renaux, K. Gysel, G. Müller, T. Brezina, T. Rordorf, M. Joerger, O.A. Michielin
Journal: Annals of Oncology (2023)
LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer
Authors: I.B. Vergote, A. Gonzalez Martin, K. Fujiwara, E. Kalbacher, A. Bagameri, S. Ghamande, J-Y. Lee, S. Banerjee, F.C. Maluf, D. Lorusso, K. Yonemori, E. Van Nieuwenhuysen, L.M. Manso Sanchez, L. Woelber, A.M. Westermann, A. Covens, E. Whalley, M.S.L. Teng, I. Soumaoro, B.M. Slomovitz
Journal: Annals of Oncology (2023)
LBA22 Connected device and therapeutic patient education to promote physical activity among in women with localized breast cancer: Results from the DISCO randomized trial
Authors: B. Fervers, B. Fournier, T. Durand, D. Perol, C. Schiffler, A. Maire, L. Perrier, M. Préau, T. Bachelot, P-E. Heudel, C. Faure, M. Heinemann, S. Kingler, D. Mouttet, L. Rossi, P. Toussaint, J. Grenier, O. Tredan, J-Y. Blay, O. Pérol
Journal: Annals of Oncology (2023)
LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial
Authors: A. Bardia, K. Jhaveri, S-A. Im, S. Pernas Simon, M. De Laurentiis, S. Wang, N. Martinez, G. Santos Borges, D.W. Cescon, M. Hattori, Y-S. Lu, E.P. Hamilton, Q.Y. Zhang, J. Tsurutani, K. Kalinsky, L. Xu, N. Denduluri, H.S. Rugo, B. Xu, B. Pistilli
Journal: Annals of Oncology (2023)
LBA41 Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): Results from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial
Authors: S.N. Westin, K.N. Moore, H.S. Chon, J-Y. Lee, J. Thomes Pepin, M. Sundborg, J. de la Garza, S. Nishio, K. Wang, K. Mcintyre, T. Tillmanns, F. Contreras Mejia, A.C. de Melo, D. Klasa-Mazurkiewicz, C.A. Papadimitriou, M. Gil Martín, B. Brasiuniene, C. Donnelly, X. Liu, E. Van Nieuwenhuysen
Journal: Annals of Oncology (2023)
LBA48 Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIb-IV melanoma from SWOG S1801
Authors: S. Patel, M. Othus, P. Wright, J. Hyngstrom, C.D. Lao, T-G. Truong, S. Chandra, K. Kendra, C. Devoe, A. Hegde, A. Mangla, M. Lowe, E. Buchbinder, J.M. Kirkwood, E. Sharon, L. Korde, J. Moon, V.K. Sondak, A. Ribas, V. Prieto
Journal: Annals of Oncology (2023)
LBA49 mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response
Authors: J.S. Weber, A. Khattak, M. Carlino, R.J. Sullivan, J.J. Luke, T. Meniawy, M. Taylor, G. Ansstas, K. Kim, M. Mckean, M. Faries, T. Tran, C.L. Cowey, A. Pecora, T. Medina, V.G. Atkinson, G. Gibney, E. Buchbinder, R. Meehan, G.V. Long
Journal: Annals of Oncology (2023)
LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer
Authors: F. Cardoso, H.L. McArthur, P. Schmid, J. Cortés, N. Harbeck, M.L. Telli, D.W. Cescon, J. O'Shaughnessy, P. Fasching, Z. Shao, D. Loirat, Y.H. Park, M.E. González Fernández, Z. Liu, H. Yasojima, Y. Ding, L. Jia, V.V. Karantza, K.E. Tryfonidis, A. Bardia
Journal: Annals of Oncology (2023)
LBA36 Efficacy and safety of senaparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer (FLAMES study): A randomized, double-blind, placebo-controlled, phase III trial
Authors: X. Wu, J. Liu, X. Wang, J. Wang, L. Wang, J. Zhu, B. Kong, J. Fei, Y. Tang, B. Xia, Z. Liang, K. Wang, Z. Lin, Y. Huang, H. Zheng, A. Lin, K. Jiang, W. Wang, X. Wang, G. Lou
Journal: Annals of Oncology (2023)
LBA40 Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma
Authors: N. Colombo, K. Harano, E. Hudson, F. Galli, Y. Antill, C.H. Choi, M. Rabaglio, F. Marmé, E. Petru, C-H. Lai, E. Biagioli, L. Fariñas Madrid, K. Takehara, K. Allan, Y.C. Lee, E. Piovano, C. Zamagni, G. Tasca, A. Ferrero, M.P. Barretina Ginesta
Journal: Annals of Oncology (2023)
LBA23 Invasive disease–free survival (iDFS) across key subgroups from the phase III NATALEE study of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2- early breast cancer (EBC)
Authors: A. Bardia, G.N. Hortobagyi, O. Lipatov, N.P. McAndrew, A. Lacko, J. Sohn, L. Hart, J.P. Crown, S-A. Im, N. Harbeck, J. O'Shaughnessy, B. Xu, C.H. Barrios, R. Moroose, V. Gonzalez, R. Fresco, F. Ghaznawi, S. Waters, A. Chakravartty, D. Slamon
Journal: Annals of Oncology (2023)
LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes
Authors: N. Harbeck, P. Rastogi, J. O'Shaughnessy, F. Boyle, J. Cortés, H.S. Rugo, M.P. Goetz, E.P. Hamilton, C. Huang, E. Senkus-Konefka, A. Tryakin, P. Neven, J. Huober, R.J. Wei, V. Andre, M. Muñoz, B. San Antonio, A. Shahir, M. Martin Jimenez, S.R.D. Johnston
Journal: Annals of Oncology (2023)
LBA27 First-line systemic treatment in patients with initially unresectable colorectal cancer liver metastases (CRLM): Overall survival of the phase III CAIRO5 study of the Dutch Colorectal Cancer Group
Authors: C.J.A. Punt, M.J.G. Bond, K. Bolhuis, O.J.L. Loosveld, J.W. de Groot, H. Droogendijk, H.H. Helgason, M.P. Hendriks, J.M. Klaase, G. Kazemier, M.S.L. Liem, A.M. Rijken, C. Verhoef, J.H.W. de Wilt, K.P. de Jong, M.J. van Amerongen, B. De Valk, E.D. Kerver, A. Komurcu, R-J. Swijnenburg
Journal: Annals of Oncology (2023)
LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer (BC)
Authors: S. Loi, G. Curigliano, R.F. Salgado, R.I. Romero Diaz, S. Delaloge, C. Rojas, M. Kok, C. Saura Manich, N. Harbeck, E.A. Mittendorf, D. Yardley, L. Pusztai, A. Suarez Zaizar, A. Ungureanu, F. Ades, R. Chandra, R. Nathani, M. Pacius, J.Q. Wu, H.L. McArthur
Journal: Annals of Oncology (2023)
LBA30 Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA): First results of the randomised phase II PANIRINOX-UCGI28 study
Authors: T. Mazard, F. Ghiringhelli, A. Winter, C. de la Fouchardiere, D. Botsen, T. André, J. Vanbockstael, M. Dos Santos, J. Martin-Babau, Y. Rinaldi, L. Evesque, S. Ellis, C. Gavoille, D. Smith, M. Fonck, D. Sefrioui, V. Pezzella, S. Nougaret, A.R. Thierry, O. Bouche
Journal: Annals of Oncology (2023)
LBA8 A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: The GCIG INTERLACE trial
Authors: M. McCormack, D. Gallardo Rincón, G. Eminowicz, P. Diez, L. Farrelly, C. Kent, E. Hudson, M. Panades, T. Mathews, A. Anand, M. Persic, J. Forrest, R. Bhana, N. Reed, A. Drake, H. Stobart, A. Mukhopadhyay, A.M. Hacker, A. Hackshaw, J.A. Ledermann
Journal: Annals of Oncology (2023)
LBA28 The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients
Authors: S. Lonardi, F. Pietrantonio, N. Tarazona Llavero, C. Montagut Viladot, A. Sartore Bianchi, M.G. Zampino, M.E. Elez Fernandez, C. Santos Vivas, M. Mandalà, S. Tamberi, M.S. Sciallero, S. Muñoz, L. Lazzari, P. Luraghi, V. Torri, A. Cervantes, A. Bardelli, J. Tabernero, S. Siena, S. Marsoni
Journal: Annals of Oncology (2023)
1014TiP Efficacy and safety of recombinant human adenovirus type 5 injection combined with transhepatic arterial embolization sequential thermal ablation for medium-and high-risk recurrent liver cancer: a prospective, open-label, randomized controlled study
Authors: J. Li, C. Jing, T. Zhu, J. Zheng, Y. Zhang
Journal: Annals of Oncology (2023)
235TiP Hamlet.rt Trans: Prospective single-centre translational study evaluating liquid biomarkers of radiation response
Authors: M. Denholm, H.W. Martin, A. Roshan, S. Miller, G. Harden, C. Towns, S. Kadyan, P. Mennea, D. Muñoz-Espín, N. Rosenfeld, G.C. Barnett, R. Rintoul, C.E. Coles, H. Yang, R. Jena
Journal: Annals of Oncology (2023)
1076TiP First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors
Authors: S. Babu, S. Kondo, N. Ammakkanavar, A.I. Spira, R. Perets, T. Doi, J. Bar, A. Vandross, D. Sommerhalder, V. Nikolic, C. Tribouley, H. Atluri, J. Hong, A. Paustian, R. Leibman, J. Powderly
Journal: Annals of Oncology (2023)
232P Identification of ‘secondary’ germline cancer predisposition variants from somatic tumour testing: Should we evolve towards universal screening?
Authors: A. Gallego Martinez, T. Imizcoz, L. Sánchez-Lorenzo, M. Mora, D. Domínguez, A. Gurpide, J. Espinos Jimenez, J.M. Aramendia, A. Chopitea Ortega, M. Santisteban Eslava, M. Ponz-Sarvise, J.L. González, A. Landa Magdalena, M.F. Sanmamed, G. Alkorta-Aranburu, J. Rodriguez Rodriguez, T. Herráiz Bayod, A. Gonzalez Martin, A. Patiño-García
Journal: Annals of Oncology (2023)
226P LongiBloodImmunoM: A multi-step analysis pipeline for longitudinal blood-based immunomonitoring for immunotherapy clinical trial
Authors: J. Ye, X. Lim, K.S. Ng, N.A. Kaya, M.C. Lau, M. Jia, C.C.L. Cheung, H.C. Toh, S.P. Choo, S.Y. Lee, J.J.X. Lee, J. Liu, T.K.H. Lim, W. Zhai, D.W.M. Tai, J.P.S. Yeong
Journal: Annals of Oncology (2023)
206P WAYFIND-R: A global, real-world database of patients (pts) with a solid tumour profiled with next-generation sequencing (NGS)
Authors: J-Y. Blay, A. Hackshaw, C. Le Tourneau, J. Geissler, A. Ferro, E. Schirgruber, O. Skatkova, R. Dienstmann
Journal: Annals of Oncology (2023)
227P Biomarkers for novel NK checkpoint inhibitor anti LLT1 antibody, ZM008: Patient transcriptome analysis
Authors: M.S. Madhusudhan, I. Garcia Ribas, M. Ghosh, A. Tiwari, A. Dubey, S. Bhattacharjee, Y. Manjunath, S. Kashipathi, S. Krishna, T. Mandal, S. Gnanasegaran, G. Rodrigues
Journal: Annals of Oncology (2023)
237TiP GUIDE.MRD: A Consortium guiding multi-modal therapies against minimal residual disease (MRD) by liquid biopsy to assess implementation of circulating tumor DNA (ctDNA) in clinical practice to improve patient outcomes
Authors: K. Pantel, C. Lindbjerg Andersen, E. Schuuring, N. Malats, E. Heitzer, L. Vat, E. Kiernan, E. Chin, J.C. Barrett, J.R. Kapp, M. Thomas, M. Gerling, M. Reck, M. Löhr, P. Hofman, J.T.J.N. Hiltermann, C. Alix-Panabières, D.J. Smit, M. Bolisetty, M. Karasarides
Journal: Annals of Oncology (2023)
224P Germline HLA-I/II is not associated with clinical outcome but the absence of HLA-A01 or the presence of HLA-B27 supertypes were correlated with improved clinical outcome among patients with NSCLC treated with pembrolizumab in combination with chemotherapy
Authors: A. Abed, A. Reid, M. Millward, E.S. Gray
Journal: Annals of Oncology (2023)
223P Artificial intelligence-based pathomics biomarker predict primary resistance to first-line treatment in metastatic colorectal cancers
Authors: G. Mauri, V. Giannini, G. Nicoletti, L. Lazzari, A. Sartore Bianchi, F. Marmorino, G. Randon, M. Nieva Munoz, N. Saoudi Gonzalez, A. Puccini, E. Berrino, C. Marchiò, M. Di Como, M.C. Aquilano, S. Arena, V. Torri, S. Siena, A. Bardelli, D. Regge, S. Marsoni
Journal: Annals of Oncology (2023)
233P Germline genetic testing before formal counseling: Impact in cancer management in a Spanish university hospital
Authors: M. Bringas Beranek, I. Echavarria Diaz-Guardamino, C. Polo, C. Flores Sanchez, A.J. Munoz Martin, L. Ortega Morán, B. Herrero Lopez, P.A. Calvo Ferrandiz, Y. Jerez Gilarranz, G. Torres Perez-Solero, S. Lopez-Tarruella Cobo, S. Gamez Casado, S. Perez Ramirez, A. Veiga Fernández, J.A. Pajares, M. Sanz, J. Suarez, M. Del Monte-Millan, M. Martin Jimenez, I. Marquez-Rodas
Journal: Annals of Oncology (2023)
1080TiP An investigator-initiated phase I study to assess the safety and tolerability of ex vivo next-generation neoantigen-selected tumor-infiltrating lymphocyte (TIL) therapy in advanced immune checkpoint blockade (ICB) resistant solid tumors (NEXTGENTIL-ACT)
Authors: V. Galvao, J. Palomero, I. Creus-Gonzalez, M.J. Lostes Bardaji, M. Lozano-Rabella, A. Garcia-Garijo, A. Yuste, L. Rodriguez, X. Villalobos Alberú, M. Rotxes, M. Vieito Villar, O. Saavedra Santa Gadea, G. Alonso, I. Braña, E. Muñoz-Couselo, S. Querol, J. Tabernero, S. Martín-Lluesma, A. Gros, E. Garralda
Journal: Annals of Oncology (2023)
548P Diffuse midline gliomas H3K27-altered in adults, the experience of an oncology center
Authors: C.F.P. Trabulo, S.C. Cabral, D. Antão, J. Costa, M. Fernandes, J. Passos Marques, J. Marques, A. Azevedo, J. Nunes, I. Costa, A.R. Marques, A. Serpa, L. Roque, M. Mafra, I.M. Matos Pina, D. Salgado
Journal: Annals of Oncology (2023)
1013TiP Refinement and validation of a comprehensive clinical diagnostic model (GAMAD) for early detection of hepatocellular carcinoma: A multicenter, prospective study protocol
Authors: T. Yang, N. Wang, X. Sun, F. Wang, Z. Fan, C. Li, F. Wang, X. Jing, M. Wang, W. Qiu, B. Yang, Y. Yang, H. Liu, H. Wang, S. Zhou, Z. Zheng, R. Liu, F. Shen, G. Lv
Journal: Annals of Oncology (2023)
230P Fibroblast growth factor receptor (FGFR) co-alteration (co-alt) landscape and its impact on erdafitinib (erda) response in the phase II open-label, single-arm RAGNAR trial
Authors: Y. Loriot, S. Pant, O. Witt, D.A. Reardon, T. Doi, S. Qin, J. Tabernero, G. Iyer, C. Massard, D. Arnold, I. Lugowska, O. Carranza, M. Gutierrez, H. Winter, H. Sweiti, S. Thomas, M. Gormley, J. Zhang, S. Triantos, M.H.H. Schuler
Journal: Annals of Oncology (2023)
1162P Prolonged exposure to proton pump inhibitors (PPI) at the time of initiation of immune checkpoint blockade (ICB) mediates better clinical outcomes in patients with metastatic melanoma
Authors: K.S. Shohdy, Y. Hatahet, T. Gillham, E.T.T. Yacoub, A. Gupta, F. Gomes, F. Thistlethwaite, F. Blackhall, P. Lorigan, N. Cook
Journal: Annals of Oncology (2023)
1077TiP TAK-500 as a single agent and in combination with pembrolizumab in patients (pts) with advanced solid tumors: Rationale and design of a phase I/II study
Authors: H. Singh, J.R. Diamond, J.T. Henry, A.J. Olszanski, D. Rasco, S.P. Patel, R. Gregory, V.A. Appleman, J.P. Gibbs, W. Zhang, C.I. Wang, A.A. Parent, V. Chung
Journal: Annals of Oncology (2023)